OXiGENE and Neoprobe Reawaken Investor Interest in Biotechnology Industry
October 21 2011 - 8:16AM
Marketwired
Drug approvals from administrative bodies in both the U.S. and
Europe have been pivotal for biotech companies recently. Investors
have been particularly sensitive to decisions made on new drugs
considering the state of the global economic recovery. The Paragon
Report examines investing opportunities in the Biotechnology
Industry and provides equity research on OXiGENE, Inc. (NASDAQ:
OXGN) and Neoprobe Corporation (NYSE Amex: NEOP). Access to the
full company reports can be found at:
www.paragonreport.com/OXGN
www.paragonreport.com/NEOP
While there are some success stories in the industry, a number
of players are having trouble dealing with the volatile nature of
biotechnologies. Research and development costs are extremely high,
and the success of a product can sometimes not be measured until
late in development. According to Krishan Maggon, a Geneva-based
pharmaceuticals consultant, the number of new biotech drugs
approved in the U.S. has remained in the 20 to 25 range during the
past four years, while in Europe the figure was a record-low 14
last year.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Neoprobe Corporation is a biomedical company focused on
enhancing oncology patient care and improving patient benefit
through radiopharmaceutical product development. Shares of the
company skyrocketed after it announced that its New Drug
Application for its radiopharmaceutical Lymphoseek (tilmanocept)
has been accepted for review by the U.S. Food and Drug
Administration (FDA). CEO Mark Pykett called FDA acceptance of the
Lymphoseek application a "positive step" for the company.
Shares of OXiGENE have also trended higher of late after the
company announced the termination of a Material Definitive
Agreement with Kingsbridge Capital Limited of its Committed Equity
Financing Facility in which Kingsbridge committed to purchase up to
$40 million of the company's common stock, subject to certain
conditions.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From Apr 2024 to May 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From May 2023 to May 2024